Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro

Y Yang, N Li, T Chen, C Zhang, J Li, L Liu, Y Qi… - Archives of …, 2019 - Springer
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor used extensively for treatment of
human tumors. However, cardiovascular adverse effects of sunitinib limit its clinical use. It is …

Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro

Y Yang, N Li, T Chen, C Zhang, J Li… - Archives of …, 2019 - pubmed.ncbi.nlm.nih.gov
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor used extensively for treatment of
human tumors. However, cardiovascular adverse effects of sunitinib limit its clinical use. It is …

Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro

Y Yang, N Li, T Chen, C Zhang, J Li… - Archives of …, 2019 - search.proquest.com
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor used extensively for treatment of
human tumors. However, cardiovascular adverse effects of sunitinib limit its clinical use. It is …

Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro.

Y Yang, N Li, T Chen, C Zhang, J Li, L Liu… - Archives of …, 2019 - europepmc.org
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor used extensively for treatment of
human tumors. However, cardiovascular adverse effects of sunitinib limit its clinical use. It is …

Sirt3 promotes sensitivity to sunitinib-induced cardiotoxicity via inhibition of GTSP1/JNK/autophagy pathway in vivo and in vitro.

Y Yang, N Li, T Chen, C Zhang, J Li, L Liu… - Archives of …, 2019 - search.ebscohost.com
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor used extensively for treatment of
human tumors. However, cardiovascular adverse effects of sunitinib limit its clinical use. It is …